$7.97
2.69% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation

Aurinia Pharmaceuticals Inc. Classifications & Recommendation:

Buy
83%
Hold
17%

Aurinia Pharmaceuticals Inc. Price Target

Target Price $9.83
Price $8.19
Potential
Number of Estimates 6
6 Analysts have issued a price target Aurinia Pharmaceuticals Inc. 2026 . The average Aurinia Pharmaceuticals Inc. target price is $9.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 5 Analysts recommend Aurinia Pharmaceuticals Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Aurinia Pharmaceuticals Inc. stock has an average upside potential 2026 of . Most analysts recommend the Aurinia Pharmaceuticals Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 235.13 258.48
33.97% 9.93%
Net Margin 2.40% 28.07%
105.53% 1,071.23%

6 Analysts have issued a sales forecast Aurinia Pharmaceuticals Inc. 2025 . The average Aurinia Pharmaceuticals Inc. sales estimate is

$258m
Unlock
. This is
9.93% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$261m 11.04%
Unlock
, the lowest is
$256m 8.79%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $235m 33.97%
2025
$258m 9.93%
Unlock
2026
$321m 24.09%
Unlock
2027
$388m 20.85%
Unlock
2028
$415m 7.07%
Unlock
2029
$415m 0.11%
Unlock

2 Aurinia Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Aurinia Pharmaceuticals Inc. net profit estimate is

$72.6m
Unlock
. This is
1,187.44% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$81.7m 1,349.99%
Unlock
, the lowest is
$63.4m 1,025.07%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $5.6m 107.41%
2025
$72.6m 1,187.44%
Unlock
2026
$91.6m 26.22%
Unlock
2027
$110m 20.01%
Unlock
2028
$128m 16.66%
Unlock
2029
$144m 12.64%
Unlock

Net Margin

2024 2.40% 105.53%
2025
28.07% 1,071.23%
Unlock
2026
28.55% 1.71%
Unlock
2027
28.35% 0.70%
Unlock
2028
30.89% 8.96%
Unlock
2029
34.75% 12.50%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.04 0.52
107.41% 1,200.00%
P/E 15.90
EV/Sales 3.27

2 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast for earnings per share. The average Aurinia Pharmaceuticals Inc. EPS is

$0.52
Unlock
. This is
1,200.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.58 1,350.00%
Unlock
, the lowest is
$0.45 1,025.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.04 107.41%
2025
$0.52 1,200.00%
Unlock
2026
$0.65 25.00%
Unlock
2027
$0.78 20.00%
Unlock
2028
$0.91 16.67%
Unlock
2029
$1.03 13.19%
Unlock

P/E ratio

Current 212.18 2,408.81%
2025
15.90 92.51%
Unlock
2026
12.60 20.75%
Unlock
2027
10.50 16.67%
Unlock
2028
9.00 14.29%
Unlock
2029
7.99 11.22%
Unlock

Based on analysts' sales estimates for 2025, the Aurinia Pharmaceuticals Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.60 33.83%
2025
3.27 9.11%
Unlock
2026
2.64 19.41%
Unlock
2027
2.18 17.26%
Unlock
2028
2.04 6.60%
Unlock
2029
2.04 0.11%
Unlock

P/S ratio

Current 4.78 15.88%
2025
4.35 9.03%
Unlock
2026
3.51 19.41%
Unlock
2027
2.90 17.25%
Unlock
2028
2.71 6.60%
Unlock
2029
2.71 0.11%
Unlock

Current Aurinia Pharmaceuticals Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Cantor Fitzgerald
Locked
Locked
Locked Sep 16 2024
Cantor Fitzgerald
Locked
Locked
Locked Sep 09 2024
HC Wainwright & Co.
Locked
Locked
Locked Sep 06 2024
Analyst Rating Date
Locked
Cantor Fitzgerald:
Locked
Locked
Sep 16 2024
Locked
Cantor Fitzgerald:
Locked
Locked
Sep 09 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 06 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today